Exact Sciences Corporation (EXAS) は上場企業です ヘルスケア セクターの Medical - Diagnostics & Research 業界で事業展開. 本社所在地は Madison, WI, アメリカ. 現CEOは Kevin T. Conroy.
EXAS を有する IPO日 2001-02-01, 6,900 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $20.03B.
Exact Sciences Corporation is a leading provider of cancer screening and diagnostic testing solutions operating across the United States and international markets. The company's flagship product, Cologuard, is a non-invasive stool-based DNA test designed to detect colorectal cancer and pre-cancerous conditions by identifying specific DNA and hemoglobin biomarkers. Beyond screening, Exact Sciences offers a comprehensive portfolio of diagnostic tests including Oncotype DX for gene expression analysis in breast, prostate, and colon cancers, as well as advanced tumor profiling and liquid-based testing solutions for metastatic and refractory cancers. The company maintains strategic partnerships with the Mayo Foundation for Medical Education and Research and Hologic, Inc., while its development pipeline focuses on enhancing existing tests and expanding into blood-based and other fluid diagnostic platforms. Founded in 1995 and headquartered in Madison, Wisconsin, Exact Sciences continues to advance precision oncology and cancer prevention.
